Conference Dates

June 12 – 17, 2022


Vaccination is critical for the prevention and control of infectious-disease outbreaks, being of paramount importance to global health, they are a key component of primary health care and an indisputable human right. Yet far too many people around the world have insufficient access to vaccines. The limited availability and affordability of vaccines to resource low-income countries has created a need for solutions that will ensure effective, affordable vaccine production technology. With potential for more pandemics, the urgency to expand vaccine range has become even more evident.

We will present a collaborative project between UCL and PT Bio Farma in which we have developed platforms to manufacture two novel immunization candidates, a recombinant virus-like-particles vaccine against Dengue disease (case study 1) and a recombinant protein vaccine against COVID-19 disease (case study 2). Both vaccines will have a social and economic impact by reducing the number of cases, and the overall mortality and morbidity.

Dengue is an emerging mosquito-borne viral infection with increasing reports of outbreaks and can be in tropical and sub-tropical areas, with Southeast Asia and the Western Pacific being the most seriously affected zones. A total of 3.8 billion people is potentially at risk, and in a scenario of global warming, this can increase to 6 billion people by 2080. To date, there is one commercialized vaccine (Sanofi-Pasteur) but is restricted to individuals aging from 9-45 years, who have been previously infected with the virus. The COVID-19 pandemic has sum approx. 400 million cases and 6 million deaths worldwide since it was first reported in 2019. Even though the production and delivery of a vaccine has significantly increased over time, the affordability, accessibility, and acceptability at individual and country levels is still a major limitation.

Please click Download on the upper right corner to see the full abstract.